Lantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions ...

Pylarify reached $1 billion in 2024 sales with 15.7% growth in the fourth quarter. The company announced two strategic acquisitions to expand diagnostic and therapeutic capabilities. Management ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand. Where to invest $1,000 ...

Central to Lantheus’ success is PYLARIFY, its flagship product for prostate cancer imaging. Analysts project PYLARIFY sales to reach $1.056 billion in 2024, representing a 23.6% year-over-year ...

Central to Lantheus’ success is PYLARIFY, its flagship product for prostate cancer imaging. Analysts project PYLARIFY sales to reach $1.056 billion in 2024, representing a 23.6% year-over-year ...

“2024 was a groundbreaking year for Lantheus, as our radiodiagnostic, PYLARIFY, reached blockbuster status, and we enhanced our radiopharmaceutical leadership,” said Brian Markison, Chief ...

Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...